| Novel and shared neoantigen derived from histone 3 variant H3. 3K27M mutation for glioma T cell therapy ZS Chheda, G Kohanbash, K Okada, N Jahan, J Sidney, M Pecoraro, ... Journal of Experimental Medicine 215 (1), 141-157, 2018 | 208 | 2018 |
| TERT promoter mutations contribute to subset prognostication of lower-grade gliomas AKY Chan, Y Yao, Z Zhang, NYF Chung, JSM Liu, KKW Li, Z Shi, ... Modern pathology 28 (2), 177-186, 2015 | 115 | 2015 |
| Combination genetic signature stratifies lower-grade gliomas better than histological grade AKY Chan, Y Yao, Z Zhang, Z Shi, L Chen, NYF Chung, JSM Liu, KKW Li, ... Oncotarget 6 (25), 20885, 2015 | 54 | 2015 |
| Targeting TBK1 to overcome resistance to cancer immunotherapy Y Sun, O Revach, S Anderson, EA Kessler, CH Wolfe, A Jenney, CE Mills, ... Nature 615 (7950), 158-167, 2023 | 36 | 2023 |
| Targeting TANK-binding kinase 1 (TBK1) in cancer OY Revach, S Liu, RW Jenkins Expert opinion on therapeutic targets 24 (11), 1065-1078, 2020 | 30 | 2020 |
| CD93+ Early Stage B Cells Interact with Dll-1 Expressing Cells in Mouse Spleen S Liu Harvard University, 2019 | | 2019 |
